Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RNA 
Avidity Biosciences Inc (RNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/27/2025: RNA (3-star) is a STRONG-BUY. BUY since 13 days. Simulated Profits (37.88%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $68.29
1 Year Target Price $68.29
| 9 | Strong Buy |
| 6 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 398.32% | Avg. Invested days 33 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/27/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.17B USD | Price to earnings Ratio - | 1Y Target Price 68.29 |
Price to earnings Ratio - | 1Y Target Price 68.29 | ||
Volume (30-day avg) 15 | Beta 0.97 | 52 Weeks Range 21.51 - 70.51 | Updated Date 10/27/2025 |
52 Weeks Range 21.51 - 70.51 | Updated Date 10/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.56 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4448.71% |
Management Effectiveness
Return on Assets (TTM) -24.01% | Return on Equity (TTM) -37.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5268000428 | Price to Sales(TTM) 668.39 |
Enterprise Value 5268000428 | Price to Sales(TTM) 668.39 | ||
Enterprise Value to Revenue 491.01 | Enterprise Value to EBITDA -5.72 | Shares Outstanding 145903337 | Shares Floating 107830794 |
Shares Outstanding 145903337 | Shares Floating 107830794 | ||
Percent Insiders 4.53 | Percent Institutions 101.82 |
Upturn AI SWOT
Avidity Biosciences Inc
Company Overview
History and Background
Avidity Biosciences Inc. was founded in 2012. It is a biotechnology company focused on developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs). They aim to treat diseases previously inaccessible to RNA therapeutics.
Core Business Areas
- AOC Platform Development: Development of Antibody Oligonucleotide Conjugates (AOCs) for targeted delivery of RNA therapeutics to specific tissues.
- Clinical Programs: Advancing a pipeline of AOC therapeutics in clinical trials, primarily focused on muscle diseases.
- Research and Discovery: Identifying and validating new AOC targets for a range of diseases.
Leadership and Structure
The leadership team is led by Sarah Boyce, CEO. The company has a typical biotech organizational structure with departments focused on research, development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- AOC 1001 (Delpacibart etedesiran): AOC 1001 is Avidity's lead product candidate for the treatment of myotonic dystrophy type 1 (DM1). There is no readily available market share data as this is in development. Competitors include pharmaceutical companies developing treatments for DM1 such as Biogen (BIIB) and Ionis Pharmaceuticals (IONS).
- AOC 1044: AOC 1044 is designed to treat Duchenne muscular dystrophy (DMD) amenable to exon 44 skipping. There is no readily available market share data as this is in development. Competitors are Sarepta Therapeutics (SRPT) with their existing DMD therapies, and other companies developing novel treatments.
Market Dynamics
Industry Overview
The industry is the RNA therapeutics market, characterized by rapid growth and innovation. This includes RNAi, mRNA, and other oligonucleotide-based therapies. There is an increasing demand for targeted therapies for genetic diseases.
Positioning
Avidity is positioned as a leader in the development of AOC therapeutics, utilizing its proprietary platform to address previously undruggable targets. Their competitive advantage lies in the specificity and targeted delivery of their AOCs.
Total Addressable Market (TAM)
The TAM for RNA therapeutics is projected to reach billions of dollars. Avidity is positioned to capture a significant share of this market with its targeted AOC approach, particularly in rare disease indications like DM1 and DMD.
Upturn SWOT Analysis
Strengths
- Proprietary AOC platform
- Targeted delivery of RNA therapeutics
- Strong clinical pipeline
- Experienced management team
- Focus on rare diseases
Weaknesses
- Reliance on AOC platform
- High R&D expenses
- Clinical trial risks
- Limited commercial experience
- Competition from established pharmaceutical companies
Opportunities
- Expansion of AOC platform to new targets
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Regulatory approvals for lead product candidates
- Growth of RNA therapeutics market
Threats
- Clinical trial failures
- Competition from alternative therapies
- Regulatory hurdles
- Intellectual property disputes
- Economic downturn impacting biotech funding
Competitors and Market Share
Key Competitors
- Sarepta Therapeutics (SRPT)
- Biogen (BIIB)
- Ionis Pharmaceuticals (IONS)
Competitive Landscape
Avidity's AOC platform offers a novel approach to targeted RNA therapeutics. Its competitive advantage lies in the specificity and delivery of its AOCs, but faces competition from established players with existing therapies and alternative approaches.
Growth Trajectory and Initiatives
Historical Growth: Discuss Avidity Biosciences Inc's growth trends over the past years. Focus on how their revenue has changed.
Future Projections: Provide projections for Avidity Biosciences Inc's future growth based on analyst estimates. These estimates can be derived from financial analyst reports from Wall Street.
Recent Initiatives: Highlight recent strategic initiatives undertaken by Avidity Biosciences Inc. New clinical studies, acquisitions, etc.
Summary
Avidity Biosciences is a clinical-stage biotech company pioneering AOC therapeutics, with a promising platform but facing clinical trial and funding risks. Their targeted approach offers a competitive edge in the growing RNA therapeutics market, but commercial success hinges on positive clinical outcomes. They need to ensure strong cash flow to fund clinical trials. Competition from bigger pharma companies is a threat but also can be an opportunity.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Avidity Biosciences Inc. Investor Relations
- SEC Filings
- Wall Street Journal
- Financial Times
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data and projections are subject to change and may not be accurate. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avidity Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2013-06-28 | President, CEO & Director Ms. Sarah Boyce | ||
Sector Healthcare | Industry Biotechnology | Full time employees 391 | |
Full time employees 391 | |||
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; Delpacibart braxlosiran that is in Phase 1/2 development stage for treating facioscapulohumeral muscular dystrophy; and Delpacibart zotadirsen, which is in the Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.